Literature DB >> 3290691

The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs.

B J Cooper1, N J Winand, H Stedman, B A Valentine, E P Hoffman, L M Kunkel, M O Scott, K H Fischbeck, J N Kornegay, R J Avery.   

Abstract

Duchenne muscular dystrophy (DMD) is the most common and the most severe of the muscular dystrophies in man. It is inherited as an X-linked recessive trait and is characterized by ongoing necrosis of skeletal muscle fibres with regeneration and eventually fibrosis and fatty infiltration. Although the gene and gene product which are defective in DMD have recently been identified, the pathogenesis of the disease is still poorly understood. A myopathy has been described in the dog which has been shown to be inherited as an X-linked trait and which is therefore a potential model of the human disease. We have studied the phenotypic expression of the disease, canine X-linked muscular dystrophy (CXMD), and have examined the molecular relationship between it and DMD. We report here that dogs with CXMD faithfully mimic the phenotype of Duchenne muscular dystrophy and that they lack the Duchenne gene transcript and its protein product, dystrophin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3290691     DOI: 10.1038/334154a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  129 in total

Review 1.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

Authors:  C A Collins; J E Morgan
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

2.  Transferring myoblasts in Duchenne dystrophy.

Authors:  V Dubowitz
Journal:  BMJ       Date:  1992-10-10

Review 3.  The muscular dystrophies.

Authors:  V Dubowitz
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

Review 4.  Animal models of muscular dystrophy.

Authors:  Rainer Ng; Glen B Banks; John K Hall; Lindsey A Muir; Julian N Ramos; Jacqueline Wicki; Guy L Odom; Patryk Konieczny; Jane Seto; Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

5.  Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy.

Authors:  Kevin J Morine; Lawrence T Bish; Joshua T Selsby; Jeffery A Gazzara; Klara Pendrak; Meg M Sleeper; Elisabeth R Barton; Se-Jin Lee; H Lee Sweeney
Journal:  Muscle Nerve       Date:  2010-11       Impact factor: 3.217

6.  Questions Answered and Unanswered by the First CRISPR Editing Study in a Canine Model of Duchenne Muscular Dystrophy.

Authors:  Nalinda B Wasala; Chady H Hakim; Shi-Jie Chen; N Nora Yang; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2019-02-26       Impact factor: 5.695

Review 7.  Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.

Authors:  Akinori Nakamura
Journal:  J Hum Genet       Date:  2017-06-01       Impact factor: 3.172

Review 8.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

9.  Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.

Authors:  Paul T Martin; G Diane Shelton; Peter J Dickinson; Beverly K Sturges; Rui Xu; Richard A LeCouteur; Ling T Guo; Robert A Grahn; Harriet P Lo; Kathryn N North; Richard Malik; Eva Engvall; Leslie A Lyons
Journal:  Neuromuscul Disord       Date:  2008-11-05       Impact factor: 4.296

Review 10.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.